There is intense excitement in the scientific community about 3D cellular model systems because they promise to resemble and recapitulate the in vivo tissue environment more faithfully than 2D systems 1 . A rapidly expanding offering of commercially available in vitro technologies for high-throughput 3D cellbased disease models, combined with advances in material sciences, are enabling widespread application and adoption of these models across academic and industrial research groups. However, there is a lack of conclusive evidence that such models accurately recapitulate in vivo tissue physiology and disease pathophysiology, and thereby provide sufficiently quantitative and reproducible data to replace current models and improve the clinical success rates of drug candidates. Prominent cellular high-content screening (HCS) and bioimage informatics societies are therefore calling for further debate to discuss the value of these emerging 3D model systems in an effort to establish more transparent and standardized guidelines in the field. Specifically, scientific community representatives highlight the lack of validated methodologies and software tools that enable robust quantitative analysis of the vast number of newer 3D cellular models.
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With this in mind, we conducted a SWOT (strengths, weaknesses, opportunities and threats) analysis of the pipeline for highcontent analysis of 3D cellular systems, divided into the four main stages: system development, imaging, screening and data analysis. Here, we summarize the main outcomes of this SWOT analysis, which are highlighted in FIG. 1 . Each point is further discussed in more depth and references are provided in Supplementary Box 1.
SWOT analysis
There have been substantial developments in the field of cell-based screening during the last decade, such as the emergence of stem cell technologies, microtissues, organoid models and organ-on-a-chip platforms. Relevant differences in cellular behaviour between 2D and 3D cultures have been characterized in several prominent studies, reporting the greater physiological relevance of 3D models compared with similar 2D models. In most cases, cells are grown embedded in extracell ular matrices to form organoids or spheroid-like structures. However, these models do not deeper penetration of light into tissue, but many areas require improvement, especially if 3D imaging is to be applied in HCS.
Given the vast amount of data generated in a HCS campaign, every byte is precious and therefore every pixel has to be of the highest quality. Importantly, given the need for extensive functional and mechanistic studies, the need to develop better imaging techniques and the vast amount of data produced in screens, our analysis highlights the lack of user-friendly analytical tools. Opensource algorithms for 3D image analysis, visualization and statistical analysis exist, but they are not accessible to biologists and require extensive computational expertise. This represents a major hurdle for the adoption, development and validation of advanced 3D model systems (see Supplementary Box 1 for more detail).
Conclusion
We believe there is a need for more early multi disciplinary collaborations, methodology guidelines, better communication and education in this field to provide the community with a more transparent assessment of the value of new 3D models and a customized toolkit for the users of 3D technologies. In addition, we call for collaborative 3D cellular model development between industry and academia to promote the adoption of standardized 3D assay technologies.
We also wish to emphasize that it is not beneficial for the field to oversell currently available models because they have neither been clinically validated nor are they likely complex enough to mimic in vivo physiology faithfully. We have often witnessed an early enthusiasm for technologies followed by disillusionment due to inflated expectations and disappointing results. In retrospect, it was clear that the technology was not mature and needed further research and development in order to better understand its shortcomings and strengths. Similarly, with 3D cell culture systems, we run the risk of disillusionment if we do not establish appropriate guidelines on how to validate a model, how to cultivate the cells, how to acquire the image data and how to analyse the resulting data. Nevertheless, with awareness of their limitations and concerted efforts to close the gaps in validating the relevance of 3D cell model systems and associated technologies, such systems may enable important advances in drug discovery and fundamental biology.
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